SCHEMBL4386877

SCHEMBL4386877

Oc1ccc(C(O)CCCCl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.54
HIF1A Q16665 2/20 0.54
HTR3A P46098 1/20 0.54
TSHR P16473 1/20 0.54
NFKB1 P19838 1/20 0.54
TDP1 Q9NUW8 3/20 0.52
KDM4E B2RXH2 2/20 0.52
ALOX15 P16050 2/20 0.52
APEX1 P27695 1/20 0.52
CYP2C9 P11712 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HTR1A P08908 1/20 0.48
THPO P40225 1/20 0.48
BLM P54132 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NMUR2 Q9GZQ4 1/20 0.48
GRIN2B Q13224 4/20 0.42
ADRA1A P35348 2/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7066863 0.86 TAAR1 (0.62) TAAR1HIF1AHTR3ATSHRNFKB1
SCHEMBL30949064 0.83 AOC3 (0.48) HIF1ATSHRNFKB1TDP1ALOX15
SCHEMBL30949073 0.83 AOC3 (0.48) HIF1ATSHRNFKB1TDP1ALOX15
SCHEMBL9772731 0.81 IGF1R (0.41)
SCHEMBL6578930 0.81 AOC3 (0.47) TSHRNFKB1KDM4EALOX15CYP2C9
SCHEMBL6579051 0.81 ALDH1A1 (0.40) TAAR1HIF1ATDP1KDM4ECYP2C9
SCHEMBL6576494 0.81 ALDH1A1 (0.40) TAAR1HIF1ATDP1KDM4ECYP2C9
SCHEMBL6577385 0.81 AOC3 (0.47) TSHRNFKB1KDM4EALOX15CYP2C9
SCHEMBL6577383 0.81 AOC3 (0.47) TSHRNFKB1KDM4EALOX15CYP2C9
SCHEMBL6576487 0.81 ALDH1A1 (0.40) TAAR1HIF1ATDP1KDM4ECYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111533804-A CD47 antibodies and methods of use thereof 印希彼有限公司 2020-08-14 CN disclosed
US-9950032-B2 Compositions and methods for lung regeneration AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) 2018-04-24 US disclosed
WO-2018057703-A1 EphA5- AND GRP78 BINDING ANTIBODIES AND USES THEREOF AND SELECTION OF PHAGE-DISPLAYED ACCESSIBLE RECOMBINANT TARGETED ANTIBODIES STC.UNM (US) 2018-03-29 WO disclosed
US-20150125490-A1 COMPOSITIONS AND METHODS FOR LUNG REGENERATION AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2015-05-07 US disclosed
US-7629380-B2 Antitumor agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-12-08 US disclosed
US-20070286872-A1 Live Attenuated Nidovirus Vaccines VANDERBILT UNIVERSITY (US) 2007-12-13 US disclosed
US-20070219174-A1 METHODS OF TREATING CANCER USING HYPOFRACTIONATED RADIATION AND TEXAPHYRINS PHARMACYCLICS, INC. (US) 2007-09-20 US disclosed
US-20070072790-A1 Antitumor agents AF CHEMICALS 2007-03-29 US disclosed
US-6855549-B1 Methods and compositions for increasing the infectivity of gene transfer vectors THE UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2005-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219174-A1 METHODS OF TREATING CANCER USING HYPOFRACTIONATED RADIATION AND TEXAPHYRINS TEX10, TEX13A, DIS3 TAAR1 2665/4885HIF1A 465/4885HTR3A 2486/4885
US-20150125490-A1 COMPOSITIONS AND METHODS FOR LUNG REGENERATION CD68, BMP4, S100B TAAR1 3947/4885HIF1A 178/4885HTR3A 4716/4885
US-20070072790-A1 Antitumor agents RB1, TP53, FOXM1 TAAR1 2147/4885HIF1A 773/4885HTR3A 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.